Request Demo
Last update 24 Jan 2026
89Zr-DFO-SC16.56
Last update 24 Jan 2026
Overview
Basic Info
Drug Type Radiolabeled antibody, Diagnostic radiopharmaceuticals |
Synonyms- |
Target |
Action modulators |
Mechanism DLL3 modulators(Delta-like protein 3 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
1
Clinical Trials associated with 89Zr-DFO-SC16.56NCT04199741
Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal Antibody
100 Clinical Results associated with 89Zr-DFO-SC16.56
Login to view more data
100 Translational Medicine associated with 89Zr-DFO-SC16.56
Login to view more data
100 Patents (Medical) associated with 89Zr-DFO-SC16.56
Login to view more data
100 Deals associated with 89Zr-DFO-SC16.56
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| DLL3 positive Small Cell Lung Cancer | Phase 2 | United States | 11 Dec 2019 | |
| Neuroendocrine Tumors | Phase 2 | United States | 11 Dec 2019 | |
| Small Cell Lung Cancer | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Prostate Neuroendocrine Carcinoma DLL3 positive | 11 | ([89Zr]Zr-DFO-SC16.56) | taltgjefnl(togmrgajps) = qmvaldfzwp yidydbwkrx (vjchuoyatu ) | - | 30 May 2025 | |
NCT04199741 (Pubmed) Manual  | Phase 1/2 | 18 | [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody (Patients with SCLC) | ucewwjdwff(pllkvvbdxk) = gxsflekmlp ivyztcppvq (rjunjisyvq, 31) View more | Positive | 01 Aug 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free